Roussel Uclaf assigns U.S. patent rights for mifepristone to the Population Council

Under pressure from anti-abortion boycott threats against its parent company Hoechst AG, Roussel Uclaf transfers U.S. patent rights for mifepristone to the Population Council, a nonprofit reproductive health organization. The transfer is a defensive maneuver: Roussel Uclaf fears U.S. market controversy will damage Hoechst''s larger pharmaceutical business, so it removes itself from the American mifepristone equation. The Population Council must now find a U.S. manufacturer willing to produce the drug despite boycott threats and navigate the full FDA approval process. This corporate retreat demonstrates how political pressure can remove private sector actors from socially contested pharmaceutical markets.